Beyond the TGF effects, whole genome RNA sequencing followed by qRT-PCR of differently expressed genes in the kidneys suggest that empagliflozin limits complement cascade-mediated renal tissue damage in nondiabetic CKD by downregulating the expression of complement components C1QA and C1QC thus contributing to the SGLT2 blocker related amelioration of CKD progression. The gene discussed is C1QC; the disease is chronic kidney disease.